Operational Update
Filed with ASX · · 7 pages · English
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Data from large animal study shows RECCE 327 well tolerated
- Appendix 4D and Interim Financial Statements
- Microscopy Images of its Synthetic Antibiotic in Action Dest
- Recce to suspend anti-cancer program
- Operational Update and Quarterly Cash Flow
Later from Recce Pharmaceuticals
- Recce moves closer to clinical study application
- Recce secures up to A$6.05 million investment agreement with
- Recce constructs automated manufacturing facility to support
- Recce achieves milestone with volume production
- Recce Confirms Delivery by Intravenous Drip
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals